146 related articles for article (PubMed ID: 18230545)
1. Susceptibility of bacterial isolates from Turkey--a report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program.
Eraksoy H; Basustaoglu A; Korten V; Kurt H; Ozturk R; Ulusoy S; Yaman A; Yuce A; Zarakolu P;
J Chemother; 2007 Dec; 19(6):650-7. PubMed ID: 18230545
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.
Kiffer CR; Mendes C; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2004 Jun; 49(2):109-16. PubMed ID: 15183860
[TBL] [Abstract][Full Text] [Related]
3. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
Zarakolu P; Hasçelik G; Unal S
Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
Korten V; Ulusoy S; Zarakolu P; Mete B;
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
[TBL] [Abstract][Full Text] [Related]
5. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
Turner PJ
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme.
Garcia-Rodriguez JA; Jones RN;
J Chemother; 2002 Feb; 14(1):25-32. PubMed ID: 11892895
[TBL] [Abstract][Full Text] [Related]
7. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.
Masterton RG; Kuti JL; Turner PJ; Nicolau DP
J Antimicrob Chemother; 2005 Jan; 55(1):71-7. PubMed ID: 15574471
[TBL] [Abstract][Full Text] [Related]
8. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
9. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
Unal S; Garcia-Rodriguez JA
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
[TBL] [Abstract][Full Text] [Related]
10. Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Mutnick AH; Turner PJ; Jones RN
J Chemother; 2002 Jun; 14(3):253-8. PubMed ID: 12120879
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
[TBL] [Abstract][Full Text] [Related]
12. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
Turner PJ
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
[TBL] [Abstract][Full Text] [Related]
13. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
[TBL] [Abstract][Full Text] [Related]
14. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008.
Wang H; Chen M; Ni Y; Liu Y; Sun H; Yu Y; Yu X; Mei Y; Liu M; Sun Z; Chu Y; Hu Z; Huang X
Int J Antimicrob Agents; 2010 Mar; 35(3):227-34. PubMed ID: 20047820
[TBL] [Abstract][Full Text] [Related]
17. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):414-26. PubMed ID: 19833471
[TBL] [Abstract][Full Text] [Related]
18. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
Pascual A; Perea E; Alvarez M; Casal M; Garcia de Lomas J; Garcia Rodríguez JA; Martin R; Soria G; Zapardiel J;
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
Rhomberg PR; Jones RN; Sader HS; Fritsche TR;
Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
[TBL] [Abstract][Full Text] [Related]
20. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
Turner PJ
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
